Innovative Trial Model Science 37's FDA-inspected direct-to-patient site model has been recognized with awards for site innovation, showcasing its ability to deliver faster enrollment and higher patient retention, making it an attractive partner for companies seeking efficient clinical trial solutions.

Decentralization Leader With recent accolades and a global award for decentralized clinical trials, Science 37 positions itself as a leader in remote trial delivery, appealing to pharmaceutical companies aiming to expand patient access and improve diversity in clinical research.

Strong Industry Recognition The company’s receipt of multiple awards including the Global Company of the Year and MedTech Breakthrough awards indicates high industry credibility and can be leveraged to build trust with potential clients looking for proven leaders in digital health and clinical innovation.

Expanding Network Partnerships such as the recent collaboration with the CGD Association of America demonstrate Science 37's active engagement with specialist organizations, presenting opportunities to tap into niche patient populations and specialized research areas.

Financial Strength With a revenue between $50M and $100M and significant funding of $69M, Science 37 has the financial resources and market traction to support large-scale deployments and customized trials, appealing to biotech and pharma companies seeking scalable clinical solutions.